Get 40% Off
💰 Warren Buffett reveals a $6.72 billion stake in ChubbCopy Portfolios

Citrix Unveils Solutions To Boost Workspace Productivity

Published 01/13/2020, 09:06 PM
Updated 07/09/2023, 06:31 AM
CTXS
-
GRMN
-
SNPS
-
KEYS
-

Citrix Systems, Inc. (NASDAQ:CTXS) recently introduced Citrix Analytics for Performance, with an aim to aid IT administrators to assess and address system performance concerns to boost employee efficiency.

The latest solution provides IT admin with clear picture of end-user’s experience with the functioning of the apps and access within Citrix Virtual Apps and Desktops.

This aids the admin to improve user experience, which in turn enhances employee engagement and improves productivity.

Moreover, the latest solution is compatible with on-premise and cloud-based Citrix Virtual Apps and Desktop installations, which is a major positive.

Real-time Visibility into Network Systems: A Key Catalyst

Notably, Citrix Virtual Apps and Desktops features real-time ML engine, which is integrated with Citrix Analytics for Performance. This facilitates IT admin to quantify users’ experience to get a user-specific “UX Score.”

UX Score takes into account machine performance, and application access parameters including network latency, user logon time, and network stability. IT admin can leverage this quantified score to evaluate and prepare a report on system performance and user experience.

Real-time visibility into network systems will aid IT admin to fix any problem concerning productivity and thereby, deliver engaging user experience.

Rise in enterprise spend on workspace productivity solutions from small and medium enterprises, is expected to bolster adoption of Citrix Analytics for Performance solution. This is anticipated to generate incremental revenues, which in turn will drive the top line in the days ahead.

Focus on Enterprise Workspace Productivity Holds Promise

Citrix is leaving no stone unturned to capitalize on increasing popularity of enterprise workspace productivity solutions.

On the back of ongoing workspace trends of Bring Your Own Devices (BYOD) and increasing number of mobile workers, the company is anticipated to benefit from strength in its workspace productivity and desktop virtualization solutions.

In fact, the company is gaining from solid adoption of unified workspace solutions and hybrid cloud offerings. Furthermore, traction witnessed by ShareFile deserves a special mention.

Notably, in third-quarter 2019, Citrix’s Workspace revenues (accounting 70% of total revenues) improved 1% year over year to $513 million courtesy of higher adoption of SaaS-bases subscription solutions.

Per ResearchAndMarkets data, business productivity software market is projected to see a CAGR of 12.6% between 2019 and 2024. The growth projection reinforces Citrix’s efforts in this domain.

Additionally, acquisitions of Cedexis and Sapho remain noteworthy. The buyouts are expected to aid Citrix in enhancing Workspace suite with guided work capabilities and traffic management functionalities.

However, increasing investments on portfolio expansion, and product enhancements, are likely to weigh on margin expansion, at least in the near term.

Zacks Rank and Key Picks

Citrix carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader technology sector are Synopsys (NASDAQ:SNPS) , Keysight Technologies (NYSE:KEYS) , and Garmin (NASDAQ:GRMN) , each flaunting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Long-term earnings growth rate for Synopsys, Keysight and Garmin is currently pegged at 12.76%, 10% and 7.35%, respectively.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Synopsys, Inc. (SNPS): Free Stock Analysis Report

Citrix Systems, Inc. (CTXS): Free Stock Analysis Report

Keysight Technologies Inc. (KEYS): Free Stock Analysis Report

Garmin Ltd. (GRMN): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.